Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?

Sameh Mikhail, Kristen Ciombor, Anne Noonan, Christina Wu, Richard Goldberg, Weiqiang Zhao, Lai Wei, Kristina Mathey, Melissa Yereb, Cynthia Timmers, Tanios Bekaii-Saab

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Targeting HER2 has improved outcomes in metastatic GE (mGE) cancer. In this study, we aim to explore the feasibility of molecular profiling in patients with refractory mGE cancer in routine clinical practice. Methods: Archival formalin-fixed, paraffin-embedded (FFPE) samples for patients with mGE were analyzed with commercially available targeted next generation sequencing (NGS) and/or FISH for MET amplification. We also reviewed the patients' medical records for concurrent HER 2 testing. Results: Tumor samples from 99 patients with mGE cancer were analyzed as follows: NGS (N = 56), FISH for MET amplification (N = 65), IHC and/or FISH for HER2 (N = 87). Of patients who underwent NGS, 50/56 (89%) had at least one actionable molecular alteration. The most notable actionable alterations included cell cycle abnormalities (58%), HER2 amplification (30%), PI3KCA mutation (14%), MCL1 amplification (11%), PTEN loss (9%), CDH1 mutation (2%) and MET amplification (5%). Ninety-two percent (12/13) of patients with HER2 amplification by NGS were positive for HER2 by IHC and/or FISH. In contrast, only 12/18 (66%) patients positive for HER2 by IHC and/or FISH demonstrated HER2 amplification by NGS. Conclusion: Comprehensive molecular testing is feasible in clinical practice and provides a platform for screening patients for molecularly guided clinical trials and available targeted therapies.

Original languageEnglish (US)
Pages (from-to)22206-22213
Number of pages8
JournalOncotarget
Volume6
Issue number26
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Neoplasms
Mutation
Paraffin
Formaldehyde
Medical Records
Cell Cycle
Clinical Trials

Keywords

  • C-MET
  • Gastro-esophageal cancer
  • Molecular profiling
  • Next generation sequencing
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Upfront molecular testing in patients with advanced gastro-esophageal cancer : Is it time yet? / Mikhail, Sameh; Ciombor, Kristen; Noonan, Anne; Wu, Christina; Goldberg, Richard; Zhao, Weiqiang; Wei, Lai; Mathey, Kristina; Yereb, Melissa; Timmers, Cynthia; Bekaii-Saab, Tanios.

In: Oncotarget, Vol. 6, No. 26, 01.01.2015, p. 22206-22213.

Research output: Contribution to journalArticle

Mikhail, S, Ciombor, K, Noonan, A, Wu, C, Goldberg, R, Zhao, W, Wei, L, Mathey, K, Yereb, M, Timmers, C & Bekaii-Saab, T 2015, 'Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?', Oncotarget, vol. 6, no. 26, pp. 22206-22213. https://doi.org/10.18632/oncotarget.4247
Mikhail S, Ciombor K, Noonan A, Wu C, Goldberg R, Zhao W et al. Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet? Oncotarget. 2015 Jan 1;6(26):22206-22213. https://doi.org/10.18632/oncotarget.4247
Mikhail, Sameh ; Ciombor, Kristen ; Noonan, Anne ; Wu, Christina ; Goldberg, Richard ; Zhao, Weiqiang ; Wei, Lai ; Mathey, Kristina ; Yereb, Melissa ; Timmers, Cynthia ; Bekaii-Saab, Tanios. / Upfront molecular testing in patients with advanced gastro-esophageal cancer : Is it time yet?. In: Oncotarget. 2015 ; Vol. 6, No. 26. pp. 22206-22213.
@article{314a63fda8ec476baf577207a1af05a4,
title = "Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?",
abstract = "Introduction: Targeting HER2 has improved outcomes in metastatic GE (mGE) cancer. In this study, we aim to explore the feasibility of molecular profiling in patients with refractory mGE cancer in routine clinical practice. Methods: Archival formalin-fixed, paraffin-embedded (FFPE) samples for patients with mGE were analyzed with commercially available targeted next generation sequencing (NGS) and/or FISH for MET amplification. We also reviewed the patients' medical records for concurrent HER 2 testing. Results: Tumor samples from 99 patients with mGE cancer were analyzed as follows: NGS (N = 56), FISH for MET amplification (N = 65), IHC and/or FISH for HER2 (N = 87). Of patients who underwent NGS, 50/56 (89{\%}) had at least one actionable molecular alteration. The most notable actionable alterations included cell cycle abnormalities (58{\%}), HER2 amplification (30{\%}), PI3KCA mutation (14{\%}), MCL1 amplification (11{\%}), PTEN loss (9{\%}), CDH1 mutation (2{\%}) and MET amplification (5{\%}). Ninety-two percent (12/13) of patients with HER2 amplification by NGS were positive for HER2 by IHC and/or FISH. In contrast, only 12/18 (66{\%}) patients positive for HER2 by IHC and/or FISH demonstrated HER2 amplification by NGS. Conclusion: Comprehensive molecular testing is feasible in clinical practice and provides a platform for screening patients for molecularly guided clinical trials and available targeted therapies.",
keywords = "C-MET, Gastro-esophageal cancer, Molecular profiling, Next generation sequencing, Targeted therapy",
author = "Sameh Mikhail and Kristen Ciombor and Anne Noonan and Christina Wu and Richard Goldberg and Weiqiang Zhao and Lai Wei and Kristina Mathey and Melissa Yereb and Cynthia Timmers and Tanios Bekaii-Saab",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.4247",
language = "English (US)",
volume = "6",
pages = "22206--22213",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - Upfront molecular testing in patients with advanced gastro-esophageal cancer

T2 - Is it time yet?

AU - Mikhail, Sameh

AU - Ciombor, Kristen

AU - Noonan, Anne

AU - Wu, Christina

AU - Goldberg, Richard

AU - Zhao, Weiqiang

AU - Wei, Lai

AU - Mathey, Kristina

AU - Yereb, Melissa

AU - Timmers, Cynthia

AU - Bekaii-Saab, Tanios

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: Targeting HER2 has improved outcomes in metastatic GE (mGE) cancer. In this study, we aim to explore the feasibility of molecular profiling in patients with refractory mGE cancer in routine clinical practice. Methods: Archival formalin-fixed, paraffin-embedded (FFPE) samples for patients with mGE were analyzed with commercially available targeted next generation sequencing (NGS) and/or FISH for MET amplification. We also reviewed the patients' medical records for concurrent HER 2 testing. Results: Tumor samples from 99 patients with mGE cancer were analyzed as follows: NGS (N = 56), FISH for MET amplification (N = 65), IHC and/or FISH for HER2 (N = 87). Of patients who underwent NGS, 50/56 (89%) had at least one actionable molecular alteration. The most notable actionable alterations included cell cycle abnormalities (58%), HER2 amplification (30%), PI3KCA mutation (14%), MCL1 amplification (11%), PTEN loss (9%), CDH1 mutation (2%) and MET amplification (5%). Ninety-two percent (12/13) of patients with HER2 amplification by NGS were positive for HER2 by IHC and/or FISH. In contrast, only 12/18 (66%) patients positive for HER2 by IHC and/or FISH demonstrated HER2 amplification by NGS. Conclusion: Comprehensive molecular testing is feasible in clinical practice and provides a platform for screening patients for molecularly guided clinical trials and available targeted therapies.

AB - Introduction: Targeting HER2 has improved outcomes in metastatic GE (mGE) cancer. In this study, we aim to explore the feasibility of molecular profiling in patients with refractory mGE cancer in routine clinical practice. Methods: Archival formalin-fixed, paraffin-embedded (FFPE) samples for patients with mGE were analyzed with commercially available targeted next generation sequencing (NGS) and/or FISH for MET amplification. We also reviewed the patients' medical records for concurrent HER 2 testing. Results: Tumor samples from 99 patients with mGE cancer were analyzed as follows: NGS (N = 56), FISH for MET amplification (N = 65), IHC and/or FISH for HER2 (N = 87). Of patients who underwent NGS, 50/56 (89%) had at least one actionable molecular alteration. The most notable actionable alterations included cell cycle abnormalities (58%), HER2 amplification (30%), PI3KCA mutation (14%), MCL1 amplification (11%), PTEN loss (9%), CDH1 mutation (2%) and MET amplification (5%). Ninety-two percent (12/13) of patients with HER2 amplification by NGS were positive for HER2 by IHC and/or FISH. In contrast, only 12/18 (66%) patients positive for HER2 by IHC and/or FISH demonstrated HER2 amplification by NGS. Conclusion: Comprehensive molecular testing is feasible in clinical practice and provides a platform for screening patients for molecularly guided clinical trials and available targeted therapies.

KW - C-MET

KW - Gastro-esophageal cancer

KW - Molecular profiling

KW - Next generation sequencing

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84941248892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941248892&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4247

DO - 10.18632/oncotarget.4247

M3 - Article

C2 - 26082439

AN - SCOPUS:84941248892

VL - 6

SP - 22206

EP - 22213

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -